Nextcure Inc Dossier
Qualitative Analysis
Business overview
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, first-in-class immunomedicines and antibody-drug conjugates (ADCs) to treat cancer and other immune-related diseases. The company utilizes its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform to identify novel targets based on immunomodulatory function. NextCure's pipeline is primarily centered on its lead clinical-stage ADC candidates: SIM0505, a CDH6-targeted ADC licensed from Simcere Zaiming, and LNCB74, a B7-H4-targeted ADC co-developed with LigaChem Biosciences. The company operates in a single reportable segment focused on life sciences.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
NextCure has prioritized its clinical-stage ADC programs, specifically SIM0505 (targeting CDH6) and LNCB74 (targeting B7-H4), while deprioritizing older non-ADC programs like NC525 and pausing internal manufacturing to align resources.
Expected impact: Extends cash runway into the first half of 2027 and focuses development on high-potential targeted oncology assets.
NextCure plans to double the number of clinical trial sites for the SIM0505 Phase 1 program in the second half of 2026, including activating sites in Canada and Europe.
Expected impact: Accelerates patient enrollment and broadens geographic clinical data representation for platinum-resistant ovarian cancer.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
NextCure acquired exclusive global rights (excluding Greater China) to develop and commercialize SIM0505, a novel CDH6-targeting ADC. NextCure also gained access to Simcere's proprietary linker and payload technology for its own preclinical ADC programs.
Terms: Simcere Zaiming is eligible to receive upfront, development, regulatory, and sales milestones up to $745 million, plus tiered double-digit royalties on net sales outside Greater China.
Co-development of LNCB74, a B7-H4-targeting ADC utilizing LigaChem's ConjuAll site-specific conjugation and plasma-stable linker technology.
Terms: 50-50 global cost-sharing and development arrangement.